Core Viewpoint - China Resources Double Crane announced participation in the 11th national centralized drug procurement, with several products expected to be selected for procurement [1] Group 1: Selected Products - The products expected to be selected include Methoclopramide injection, Meprobamate injection, Famotidine injection, and Piracetam oral sustained-release formulation [1] - The proposed procurement prices are as follows: Methoclopramide injection at 0.68 CNY per unit, Meprobamate injection at 9.78 CNY per unit, Famotidine injection at 0.42 CNY per unit, and Piracetam oral sustained-release formulation at 7.87 CNY per bottle [1]

Core Viewpoint - The company, Huilong Pharmaceutical, announced its subsidiary's participation in the 11th national centralized drug procurement organized by the National Drug Procurement Office, with one product, Meisobam Injection, expected to win the bid [1] Group 1 - The company’s subsidiary, Sichuan Huilong Haiyue Pharmaceutical Technology Co., Ltd., is involved in the bidding process for centralized drug procurement [1] - The product Meisobam Injection is anticipated to be awarded in this procurement round [1] - The product is expected to receive its drug registration certificate from the National Medical Products Administration in October 2024, and has not generated any sales revenue prior to this bid [1]